Sandbox Reserved 1736
From Proteopedia
(Difference between revisions)
Line 2: | Line 2: | ||
<StructureSection load='7qus' size='350' side='right' caption='C3 symmetry of SARS-CoV-2 spike protein' scene=''> | <StructureSection load='7qus' size='350' side='right' caption='C3 symmetry of SARS-CoV-2 spike protein' scene=''> | ||
==SARS-CoV-2 Spike Protein== | ==SARS-CoV-2 Spike Protein== | ||
- | The SARS-CoV-2 spike protein (Severe acute respiratory syndrome coronavirus 2) is a protein that has emerged from the COVID-19 virus beginning in December 2019. It has had a significant global impact on human health.<ref>Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Luchsinger, L.; Hillyer, C. D.; Caskey, M.; Robbiani, D. F.; Rice, C. M.; Nussenzweig, M. C.; Hatziioannou, T.; Bieniasz, P. D. Escape from Neutralizing Antibodies by SARS-COV-2 Spike Protein Variants. eLife '''2020''', 9.</ref> The spike protein is a major immunogenic target for virus neutralization and is the current focus of many vaccine development efforts.<ref>Henderson, R.; Edwards, R. J.; Mansouri, K.; Janowska, K.; Stalls, V.; Gobeil, S.; Kopp, M.; Hsu, A.; Borgnia, M.; Parks, R.; Haynes, B. F.; Acharya, P. Controlling the SARS-COV-2 Spike Glycoprotein Conformation | + | The SARS-CoV-2 spike protein (Severe acute respiratory syndrome coronavirus 2) is a protein that has emerged from the COVID-19 virus beginning in December 2019. It has had a significant global impact on human health.<ref>Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Luchsinger, L.; Hillyer, C. D.; Caskey, M.; Robbiani, D. F.; Rice, C. M.; Nussenzweig, M. C.; Hatziioannou, T.; Bieniasz, P. D. Escape from Neutralizing Antibodies by SARS-COV-2 Spike Protein Variants. eLife '''2020''', 9.</ref> The spike protein is a major immunogenic target for virus neutralization and is the current focus of many vaccine development efforts.<ref>Henderson, R.; Edwards, R. J.; Mansouri, K.; Janowska, K.; Stalls, V.; Gobeil, S.; Kopp, M.; Hsu, A.; Borgnia, M.; Parks, R.; Haynes, B. F.; Acharya, P. Controlling the SARS-COV-2 Spike Glycoprotein Conformation '''2020'''.</ref> The virus is still present as of 2022. Most people infected with the disease experience an array of symptoms including fever, headaches, fatigue, sore throat, cough, etc. The spike protein is on the surface of the SARS-CoV-2 virus which then initiate infection in host cells.<ref name="bangaru">Bangaru, S.; Ozorowski, G.; Turner, H. L.; Antanasijevic, A.; Huang, D.; Wang, X.; Torres, J. L.; Diedrich, J. K.; Tian, J.-H.; Portnoff, A. D.; Patel, N.; Massare, M. J.; Yates, J. R.; Nemazee, D.; Paulson, J. C.; Glenn, G.; Smith, G.; Ward, A. B. Structural Analysis of Full-Length SARS-COV-2 Spike Protein from an Advanced Vaccine Candidate. Science '''2020''', 370 (6520), 1089–1094.</ref> |
== Function == | == Function == | ||
The SARS-CoV-2 spike protein helps extract antibodies that neutralize viruses into the body. To enter a cell and start an infection, the spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human <scene name='91/919045/Ace2_sars-cov-2_spike_protein/1'>ACE2</scene> receptor. The ACE2 (Angiotensin-converting enzyme 2) is an enzyme that can be found in the membrane of cells in the following: intestines, kidney, testis, gallbladder, and heart.<ref>Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses '''2021''', 13(1).</ref> The spike (S) protein has the following: S1 and S2 subunits, extracellular N-terminus, a transmembrane domain that is being anchored into the viral membrane, and a short intracellular C-terminal. In the native state– the protein is folded to be able to operate and function properly. In this case the SARS-CoV-2 spike protein begins to exist as an inactive precursor when in this specific state. However, in a viral infection state, the target cell's proteases will activate the S-protein which is being cleaved into both the S1 and S2 subunits. As a result, this allows for the activation of the membrane fusion after the result of viral entry are in the targeted cells.<ref name="huang">Huang, Y.; Yang, C.; Xu, X.-feng; Xu, W.; Liu, S.-wen. Structural and Functional Properties of SARS-COV-2 Spike Protein: Potential Antivirus Drug Development for Covid-19. Acta Pharmacologica Sinica '''2020''', 41 (9), 1141–1149.</ref> The S typically exists in a metastable– where it will have no small disturbances, prefusion conformation.<ref name="bangaru">Bangaru, S.; Ozorowski, G.; Turner, H. L.; Antanasijevic, A.; Huang, D.; Wang, X.; Torres, J. L.; Diedrich, J. K.; Tian, J.-H.; Portnoff, A. D.; Patel, N.; Massare, M. J.; Yates, J. R.; Nemazee, D.; Paulson, J. C.; Glenn, G.; Smith, G.; Ward, A. B. Structural Analysis of Full-Length SARS-COV-2 Spike Protein from an Advanced Vaccine Candidate. Science '''2020''', 370 (6520), 1089–1094.</ref> | The SARS-CoV-2 spike protein helps extract antibodies that neutralize viruses into the body. To enter a cell and start an infection, the spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human <scene name='91/919045/Ace2_sars-cov-2_spike_protein/1'>ACE2</scene> receptor. The ACE2 (Angiotensin-converting enzyme 2) is an enzyme that can be found in the membrane of cells in the following: intestines, kidney, testis, gallbladder, and heart.<ref>Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses '''2021''', 13(1).</ref> The spike (S) protein has the following: S1 and S2 subunits, extracellular N-terminus, a transmembrane domain that is being anchored into the viral membrane, and a short intracellular C-terminal. In the native state– the protein is folded to be able to operate and function properly. In this case the SARS-CoV-2 spike protein begins to exist as an inactive precursor when in this specific state. However, in a viral infection state, the target cell's proteases will activate the S-protein which is being cleaved into both the S1 and S2 subunits. As a result, this allows for the activation of the membrane fusion after the result of viral entry are in the targeted cells.<ref name="huang">Huang, Y.; Yang, C.; Xu, X.-feng; Xu, W.; Liu, S.-wen. Structural and Functional Properties of SARS-COV-2 Spike Protein: Potential Antivirus Drug Development for Covid-19. Acta Pharmacologica Sinica '''2020''', 41 (9), 1141–1149.</ref> The S typically exists in a metastable– where it will have no small disturbances, prefusion conformation.<ref name="bangaru">Bangaru, S.; Ozorowski, G.; Turner, H. L.; Antanasijevic, A.; Huang, D.; Wang, X.; Torres, J. L.; Diedrich, J. K.; Tian, J.-H.; Portnoff, A. D.; Patel, N.; Massare, M. J.; Yates, J. R.; Nemazee, D.; Paulson, J. C.; Glenn, G.; Smith, G.; Ward, A. B. Structural Analysis of Full-Length SARS-COV-2 Spike Protein from an Advanced Vaccine Candidate. Science '''2020''', 370 (6520), 1089–1094.</ref> |
Current revision
Structure
|
References
- ↑ Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Luchsinger, L.; Hillyer, C. D.; Caskey, M.; Robbiani, D. F.; Rice, C. M.; Nussenzweig, M. C.; Hatziioannou, T.; Bieniasz, P. D. Escape from Neutralizing Antibodies by SARS-COV-2 Spike Protein Variants. eLife 2020, 9.
- ↑ Henderson, R.; Edwards, R. J.; Mansouri, K.; Janowska, K.; Stalls, V.; Gobeil, S.; Kopp, M.; Hsu, A.; Borgnia, M.; Parks, R.; Haynes, B. F.; Acharya, P. Controlling the SARS-COV-2 Spike Glycoprotein Conformation 2020.
- ↑ 3.0 3.1 Bangaru, S.; Ozorowski, G.; Turner, H. L.; Antanasijevic, A.; Huang, D.; Wang, X.; Torres, J. L.; Diedrich, J. K.; Tian, J.-H.; Portnoff, A. D.; Patel, N.; Massare, M. J.; Yates, J. R.; Nemazee, D.; Paulson, J. C.; Glenn, G.; Smith, G.; Ward, A. B. Structural Analysis of Full-Length SARS-COV-2 Spike Protein from an Advanced Vaccine Candidate. Science 2020, 370 (6520), 1089–1094.
- ↑ Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses 2021, 13(1).
- ↑ 5.0 5.1 Huang, Y.; Yang, C.; Xu, X.-feng; Xu, W.; Liu, S.-wen. Structural and Functional Properties of SARS-COV-2 Spike Protein: Potential Antivirus Drug Development for Covid-19. Acta Pharmacologica Sinica 2020, 41 (9), 1141–1149.
- ↑ Suzuki, Y. J.; Gychka, S. G. SARS-COV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of Covid-19 Vaccines. Vaccines 2021, 9 (1), 36.
- ↑ Jackson, C. B.; Zhang, L.; Farzan, M.; Choe, H. Functional Importance of the D614G Mutation in the SARS-COV-2 Spike Protein. Biochemical and Biophysical Research Communications 2021, 538, 108–115.
- ↑ Guruprasad, L. Human Sars-CoV‐2 Spike Protein Mutations. Proteins: Structure, Function, and Bioinformatics 2021, 89 (5), 569–576.
- ↑ Berger, I.; Schaffitzel, C. The Sars-COV-2 Spike Protein: Balancing Stability and Infectivity. Cell Research 2020, 30 (12), 1059–1060.
- ↑ Zhou, T.; Tsybovsky, Y.; Gorman, J.; Rapp, M.; Cerutti, G.; Chuang, G.-Y.; Katsamba, P. S.; Sampson, J. M.; Schön, A.; Bimela, J.; Boyington, J. C.; Nazzari, A.; Olia, A. S.; Shi, W.; Sastry, M.; Stephens, T.; Stuckey, J.; Teng, I.-T.; Wang, P.; Wang, S.; Zhang, B.; Friesner, R. A.; Ho, D. D.; Mascola, J. R.; Shapiro, L.; Kwong, P. D. Cryo-EM Structures of SARS-COV-2 Spike without and with Ace2 Reveal a Ph-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host & Microbe 2020, 28 (6).